Evidence from preclinical studies suggests a preventive effect of proton pump inhibitors (PPIs) in preeclampsia. Recently, several epidemiological studies have described a conflicting association between the use of PPIs during pregnancy and preeclampsia risk. This study aimed to evaluate the association between PPI use and the risk of preeclampsia. We searched databases, including MEDLINE, Embase, Scopus, Web of Science Core Collection, Emcare, CINAHL, and the relevant grey literature from inception until 13 September 2021. Studies reporting the preeclampsia risk with the use of PPIs were eligible for inclusion. Literature screening, data extraction, and the risk of bias assessment were performed independently by two investigators. Random-effect meta-analysis was performed to generate relative risks (RR) and 95% confidence intervals (CI). The risk of preeclampsia and preterm preeclampsia among women receiving PPIs during pregnancy were the primary outcomes of interest. This meta-analysis comprised three studies involving 4,877,565 pregnant women, of whom 119,017 were PPI users. The included studies were judged to have a low risk of bias. The risk of preeclampsia among pregnant women who received PPIs anytime during pregnancy was significantly increased (RR 1.27 (95% CI: 1.23-1.31)), although the increase was trivial in absolute terms (2 per 1000). The subgroup analysis revealed that the risk was increased in each of the three trimesters. The risk of preterm preeclampsia among pregnant women receiving PPIs anytime during pregnancy was not significantly increased (RR 1.04 (95% CI: 0.70-1.55)). The certainty evaluated by GRADE in these estimates was low. PPI use may be associated with a trivial increase in the risk of preeclampsia in pregnant women. There is no evidence supporting that PPI use decreases the risk of preeclampsia or preterm preeclampsia.

Czech National Centre for Evidence Based Healthcare and Knowledge Translation Institute of Biostatistics and Analyses Faculty of Medicine Masaryk University Brno Czech Republic Kamenice 5 62500 Brno Czech Republic

Department of Obstetrics and Gynaecology All India Institute of Medical Sciences New Delhi 110029 India

Division of Public Health Infectious Diseases and Occupational Medicine Mayo Clinic 200 1st St SW Rochester MN 55905 USA

Menzies Institute for Medical Research University of Tasmania 17 Liverpool St Hobart TAS 7000 Australia

Zobrazit více v PubMed

Wang W., Xie X., Yuan T., Wang Y., Zhao F., Zhou Z., Zhang H. Epidemiological trends of maternal hypertensive disorders of pregnancy at the global, regional, and national levels: A population-based study. BMC Pregnancy Childbirth. 2021;21:364. doi: 10.1186/s12884-021-03809-2. PubMed DOI PMC

Mayrink J., Souza R., Feitosa F.E., Filho E.A.R., Leite D., Vettorazzi J., Calderon I., Sousa M.H., Costa M.L., Preterm SAMBA study group et al. Incidence and risk factors for Preeclampsia in a cohort of healthy nulliparous pregnant women: A nested case-control study. Sci. Rep. 2019;9:9517. doi: 10.1038/s41598-019-46011-3. PubMed DOI PMC

García-Basteiro A.L., Quintó L., Macete E., Bardají A., González R., Nhacolo A., Sigauque B., Sacoor C., Rupérez M., Sicuri E., et al. Infant mortality and morbidity associated with preterm and small-for-gestational-age births in Southern Mozambique: A retrospective cohort study. PLoS ONE. 2017;12:e0172533. doi: 10.1371/journal.pone.0172533. PubMed DOI PMC

Crump C., Sundquist J., Sundquist K. Preterm delivery and long term mortality in women: National cohort and co-sibling study. BMJ. 2020;370:m2533. doi: 10.1136/bmj.m2533. PubMed DOI PMC

D’Onofrio B.M., Class Q.A., Rickert M.E., Larsson H., Långström N., Lichtenstein P. Preterm birth and mortality and morbidity: A population-based quasi-experimental study. JAMA Psychiatry. 2013;70:1231–1240. doi: 10.1001/jamapsychiatry.2013.2107. PubMed DOI PMC

Hannan N.J., Kaitu’u-Lino T.U., Tuohey L., Brownfoot F., Tong S., Onda K. Reproductive Sciences. Sage Publications Inc.; Thousand Oaks, CA, USA: 2014. Proton Pump Inhibitors Induce Heme-Oxygenase-1 and Decrease sFlt1 and sEng Production in Primary Placental and Endothelial Cells: A Novel Candidate Therapeutic for Preeclampsia.

Onda K., Hannan N., Beard S. [6-OR]: Proton pump inhibitors for treatment of preeclampsia. Pregnancy Hypertens. Int. J. Women’s Cardiovasc. Health. 2015;5:3.

Onda K., Tong S., Beard S., Binder N., Muto M., Senadheera S.N., Parry L., Dilworth M., Renshall L., Brownfoot F., et al. Proton Pump Inhibitors Decrease Soluble fms-Like Tyrosine Kinase-1 and Soluble Endoglin Secretion, Decrease Hypertension, and Rescue Endothelial Dysfunction. Hypertension. 2017;69:457–468. doi: 10.1161/HYPERTENSIONAHA.116.08408. PubMed DOI

Tong S., Tu’uhevaha J., Hastie R., Brownfoot F., Cluver C., Hannan N. Pravastatin, proton pump inhibitors, metformin, micronutrients and biologics: New horizons for the prevention or treatment of preeclampsia. Am. J. Obstet. Gynecol. 2020;226:S1157–S1170. doi: 10.1016/j.ajog.2020.09.014. PubMed DOI

Binder N.K., Brownfoot F.C., Beard S., Cannon P., Nguyen T.V., Tong S., Kaitu’U-Lino T.J., Hannan N.J. Esomeprazole and sulfasalazine in combination additively reduce sFlt-1 secretion and diminish endothelial dysfunction: Potential for a combination treatment for preeclampsia. Pregnancy Hypertens. Health. 2020;22:86–92. doi: 10.1016/j.preghy.2020.07.013. PubMed DOI

Saleh L., Samantar R., Garrelds I.M., Meiracker A.H.V.D., Visser W., Danser A.J. Low Soluble Fms-Like Tyrosine Kinase-1, Endoglin, and Endothelin-1 Levels in Women with Confirmed or Suspected Preeclampsia Using Proton Pump Inhibitors. Hypertension. 2017;70:594–600. doi: 10.1161/HYPERTENSIONAHA.117.09741. PubMed DOI

Des Varannes S.B., Coron E., Galmiche J.-P. Short and long-term PPI treatment for GERD. Do we need more-potent anti-secretory drugs? Best Pract. Res. Clin. Gastroenterol. 2010;24:905–921. doi: 10.1016/j.bpg.2010.09.004. PubMed DOI

Hussain S., Siddiqui A.N., Habib A., Hussain S., Najmi A.K. Proton pump inhibitors’ use and risk of hip fracture: A systematic review and meta-analysis. Rheumatol. Int. 2018;38:1999–2014. doi: 10.1007/s00296-018-4142-x. PubMed DOI

Hussain S., Singh A., Habib A., Najmi A.K. Proton pump inhibitors use and risk of chronic kidney disease: Evidence-based meta-analysis of observational studies. Clin. Epidemiol. Glob. Health. 2019;7:46–52. doi: 10.1016/j.cegh.2017.12.008. DOI

Hussain S., Singh A., Zameer S., Jamali M.C., Baxi H., Rahman S.O., Alam M., Altamish M., Singh A.K., Anil D., et al. No association between proton pump inhibitor use and risk of dementia: Evidence from a meta-analysis. J. Gastroenterol. Hepatol. 2020;35:19–28. doi: 10.1111/jgh.14789. PubMed DOI

Singh A., Hussain S., Jha R., Jayraj A.S., Klugar M., Antony B. Proton pump inhibitor use and the risk of hepatocellular carcinoma: A systematic review of pharmacoepidemiological data. J. Evid. Based Med. 2021;14:278–280. doi: 10.1111/jebm.12456. PubMed DOI

Johnson D.A., Katz P.O., Armstrong D., Cohen H., Delaney B.C., Howden C.W., Katelaris P., Tutuian R.I., Castell D.O. The Safety of Appropriate Use of Over-the-Counter Proton Pump Inhibitors: An Evidence-Based Review and Delphi Consensus. Drugs. 2017;77:547–561. doi: 10.1007/s40265-017-0712-6. PubMed DOI PMC

Pasternak B., Hviid A. Use of Proton-Pump Inhibitors in Early Pregnancy and the Risk of Birth Defects. N. Engl. J. Med. 2010;363:2114–2123. doi: 10.1056/NEJMoa1002689. PubMed DOI

Li C.M., Zhernakova A., Engstrand L., Wijmenga C., Brusselaers N. Systematic review with meta-analysis: The risks of proton pump inhibitors during pregnancy. Aliment. Pharmacol. Ther. 2020;51:410–420. doi: 10.1111/apt.15610. PubMed DOI

Hastie R., Bergman L., Cluver C.A., Wikman A., Hannan N.J., Walker S.P., Wikström A., Tong S., Hesselman S. Proton Pump Inhibitors and Preeclampsia Risk Among 157 720 Women: A Swedish Population Register–Based Cohort Study. Hypertension. 2019;73:1097–1103. doi: 10.1161/HYPERTENSIONAHA.118.12547. PubMed DOI

Choi A., Noh Y., Park S.-H., Choe S.-A., Shin J.-Y. Exploration of Proton Pump Inhibitors Use During Pregnancy and Preeclampsia. JAMA Netw. Open. 2021;4:e2124339. doi: 10.1001/jamanetworkopen.2021.24339. PubMed DOI PMC

Bello N.A., Huang Y., Syeda S.K., Wright J.D., D’Alton M.E., Friedman A.M. Receipt of Proton-Pump Inhibitors during Pregnancy and Risk for Preeclampsia. Am. J. Perinatol. 2020;38:1519–1525. doi: 10.1055/s-0040-1713864. PubMed DOI

Hussain S., Singh A., Antony B., Klugarová J., Klugar M. Proton pump inhibitors use and risk of preeclampsia. medRxiv. 2021 doi: 10.1101/2021.09.15.21263602. PubMed DOI PMC

Aromataris E., Munn Z., editors. JBI Manual for Evidence Synthesis. JBI; Adelaide, Australia: 2020.

Higgins J., Thomas J. Cochrane Handbook for Systematic Reviews of Interventions. 2nd ed. John Wiley and Sons, Ltd.; Chichester, UK: 2019. pp. 143–176.

Page M.J., McKenzie J.E., Bossuyt P.M., Boutron I., Hoffmann T.C., Mulrow C.D., Shamseer L., Tetzlaff J.M., Akl E.A., Brennan S.E., et al. The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. BMJ. 2021;88:105906. PubMed

Stroup D.F., Berlin J.A., Morton S.C., Olkin I., Williamson G.D., Rennie D., Moher D., Becker B.J., Sipe T.A., Thacker S.B. Meta-analysis of observational studies in epidemiology: A proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA. 2008;283:2008–2012. doi: 10.1001/jama.283.15.2008. PubMed DOI

Hussain S., Singh A., Antony BS E., Kulgarova J., Licenik R., Klugar M. Association of acute kidney injury with the risk of dementia: A meta-analysis protocol. medRxiv. 2021 doi: 10.1101/2021.07.27.21261192. PubMed DOI PMC

Wells G.A., Shea B., O’Connell D., Peterson J., Welch V., Losos M., Tugwell P. The Newcastle-Ottawa Scale (NOS) for Assessing the Quality of Nonrandomised Studies in Meta-Analyses. 2000. [(accessed on 4 October 2021)]. Available online: https://www.ohri.ca//programs/clinical_epidemiology/oxford.asp.

Viswanathan M., Patnode C.D., Berkman N.D., Bass E., Chang S., Hartling L., Murad M.H., Treadwell J.R., Kane R.L. Recommendations for assessing the risk of bias in systematic reviews of health-care interventions. J. Clin. Epidemiol. 2018;97:26–34. doi: 10.1016/j.jclinepi.2017.12.004. PubMed DOI

Group G.W. Grading quality of evidence and strength of recommendations. BMJ. 2004;328:1490. PubMed PMC

Kwok C.S., Jeevanantham V., Dawn B., Loke Y.K. No consistent evidence of differential cardiovascular risk amongst proton-pump inhibitors when used with clopidogrel: Meta-analysis. Int. J. Cardiol. 2013;167:965–974. doi: 10.1016/j.ijcard.2012.03.085. PubMed DOI

Singh A., Hussain S., Najmi A.K. Number of studies, heterogeneity, generalisability, and the choice of method for meta-analysis. J. Neurol. Sci. 2017;381:347. doi: 10.1016/j.jns.2017.09.026. PubMed DOI

McMaster University Evidence Prime. GRADEpro GDT: GRADEpro Guideline Development Tool [Software] 2022. [(accessed on 4 October 2021)]. Available online: gradepro.org.

Cluver C.A., Hannan N.J., van Papendorp E., Hiscock R., Beard S., Mol B.W., Theron G.B., Hall D.R., Decloedt E.H., Stander M., et al. Esomeprazole to treat women with preterm preeclampsia: A randomized placebo controlled trial. Am. J. Obstet. Gynecol. 2018;219:388.e1–388.e17. doi: 10.1016/j.ajog.2018.07.019. PubMed DOI

Abbas A.M., Othman Y.M., Abdallah M.M., Ellah N.H.A., Azim H.G.A., Shaamash A.H. Effect of esomeprazole on maternal serum soluble fms-like tyrosine kinase-1 and endoglin in patients with early-onset preeclampsia. Proc. Obstet. Gynecol. 2021;99:1–14. doi: 10.17077/2154-4751.28690. DOI

Ramu B., Mohan P., Rajasekaran M.S., Jayanthi V. Prevalence and risk factors for gastroesophageal reflux in pregnancy. Indian J. Gastroenterol. 2010;30:144–147. doi: 10.1007/s12664-010-0067-3. PubMed DOI

Poorolajal J., Jenabi E. The association between body mass index and preeclampsia: A meta-analysis. J. Matern. Neonatal Med. 2016;29:3670–3676. doi: 10.3109/14767058.2016.1140738. PubMed DOI

Proton Pump Inhibitors Use and Risk of Preeclampsia: A Meta-Analysis